These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

23 related articles for article (PubMed ID: 18720164)

  • 1. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.
    Kuno A; Ikehara Y; Tanaka Y; Ito K; Matsuda A; Sekiya S; Hige S; Sakamoto M; Kage M; Mizokami M; Narimatsu H
    Sci Rep; 2013; 3():1065. PubMed ID: 23323209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gal-3BP in Viral Infections: An Emerging Role in Severe Acute Respiratory Syndrome Coronavirus 2.
    Gallo V; Arienzo A; Iacobelli S; Iacobelli V; Antonini G
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis.
    Maekawa T; Kamada Y; Ebisutani Y; Ueda M; Hata T; Kawamoto K; Takamatsu S; Mizutani K; Shimomura M; Sobajima T; Fujii H; Nakayama K; Nishino K; Yamada M; Kumada T; Ito T; Eguchi H; Nagano H; Miyoshi E
    World J Gastroenterol; 2016 May; 22(17):4403-10. PubMed ID: 27158210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C.
    Tawara S; Tatsumi T; Iio S; Kobayashi I; Shigekawa M; Hikita H; Sakamori R; Hiramatsu N; Miyoshi E; Takehara T
    PLoS One; 2016; 11(3):e0151828. PubMed ID: 27002630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL28B genotype and the expression of ISGs in normal liver.
    Raglow Z; Thoma-Perry C; Gilroy R; Wan YJ
    Liver Int; 2013 Aug; 33(7):991-8. PubMed ID: 23522062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
    Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
    Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Hashimoto Y; Ochi H; Abe H; Hayashida Y; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Nelson Hayes C; Ohishi W; Kubo M; Tsunoda T; Kamatani N; Nakamura Y; Chayama K
    J Med Virol; 2011 Jun; 83(6):981-8. PubMed ID: 21503910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
    McPhee F; Hernandez D; Zhou N; Yu F; Ueland J; Monikowski A; Chayama K; Toyota J; Izumi N; Yokosuka O; Kawada N; Osaki Y; Hughes EA; Watanabe H; Ishikawa H; Kumada H
    Antivir Ther; 2014; 19(5):479-90. PubMed ID: 24448487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
    Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in HCV chronic patients.
    Iacovazzi PA; Cozzolongo R; Lanzillotta E; Frisullo S; Guerra V; Correale M
    Immunopharmacol Immunotoxicol; 2008; 30(4):687-700. PubMed ID: 18720164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
    Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.